Pacira Biosciences Inc PCRX:NASDAQ

Last Price$43.82NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/17/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$43.82 (50)
Ask (Size)$43.84 (1)
Day Low / HighN/A - N/A
Volume626.5 K
  • Latest Stories
  • Commentary and Analysis
Pacira Pre-Announces Q4 Revenue Above Street View
8:37AM ET 1/09/2020 MT Newswires

Pacira BioSciences (PCRX), a provider of innovative non-opioid pain management options, reported pre-market Thursday preliminary Q4 revenue of $122.4...

Earnings Forecast for Pacira Biosciences in 2020 Targeted Higher
12:45AM ET 1/09/2020 MT Newswires

2020`s forecasted earnings estimate for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 43.10) for the year ending December 31, 2020 has been increased....

2020 Earnings Estimate for Pacira Biosciences Reduced
1:10AM ET 1/08/2020 MT Newswires

The 2020 forecasted earnings estimate for Pacira Biosciences Inc's (NASDAQ:PCRX, Recent Price: 42.59) for the year ending December 31, 2020 has been...

Pacira Pharmaceuticals Reports Positive Results from Study of Exparel in Cesarean Section Patients
8:54AM ET 1/07/2020 MT Newswires

Pacira Pharmaceuticals (PCRX) reported that its phase 4 study of Exparel, an injectable drug for patients undergoing a Cesarean section, achieved its...

Insider Trends: Insider Prolongs 90-Day Selling Trend at Pacira Biosciences
6:56PM ET 12/18/2019 MT Newswires

Dennis McLoughlin, Chief Commercial Officer, sold 3,671 shares in Pacira Biosciences (PCRX) for $168,108 on Dec 16, 2019. Following the Form 4 filing with...

Pacira Pharmaceuticals Says Study Shows No Safety Concerns for Exparel in Pediatric Patients
8:51AM ET 12/17/2019 MT Newswires

Pacira Pharmaceuticals (PCRX) on Tuesday released results a phase 3 clinical trial of its pain medicine Exparel on pediatric patients undergoing spinal or...

Q4, 2019, 2020 Earnings Estimates for Pacira Biosciences Raised
3:06AM ET 11/09/2019 MT Newswires

Consensus estimates for Q4 ending December 31, 2019, and the full year forecasts for 2019 and 2020 for the years ending on December 31 for Pacira...

2019 Estimate for Pacira Biosciences Scaled Up but 2020 Earnings Number Scaled Down
2:56AM ET 11/08/2019 MT Newswires

The full year forecasted earnings estimates for 2019 and 2020 for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 42.62) have been changed. The...

Pacira BioSciences Q3 Non-GAAP EPS Beats, Revenue Just Short of Expectations
10:03AM ET 11/07/2019 MT Newswires

Pacira BioSciences (PCRX) on Thursday reported Q3 non-GAAP EPS of $0.48, compared with $0.31 a year earlier and the Capital IQ consensus forecast of $0.33....

Analyst Actions: BTIG Research Initiates Coverage on Pacira Pharmaceuticals With Buy Rating, $56 PT
9:33AM ET 11/06/2019 MT Newswires

Pacira Pharmaceuticals' (PCRX) average rating among analysts is a hold, with an average price target of $54. Price: 43.30, Change: +1.08, Percent Change:...